36 Recruiting Metastatic Colorectal Cancer Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Metastatic Colorectal Cancer
Top Recruiting Metastatic Colorectal Cancer Studies
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
📍 Mayo Clinic Building - Phoenix — Phoenix, Arizona
View Study & Checklist ➔Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
📍 Sunnybrook Odette Cancer Centre — Toronto, Ontario
View Study & Checklist ➔A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
📍 Local Institution - 0059 — Los Angeles, California
View Study & Checklist ➔A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
📍 City of Hope National Medical Center /ID# 267875 — Duarte, California
View Study & Checklist ➔A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
📍 Summit Therapeutics Research Site — Los Angeles, California
View Study & Checklist ➔Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
📍 Mayo Clinic - Arizona — Phoenix, Arizona
View Study & Checklist ➔Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
📍 University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
View Study & Checklist ➔A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
📍 HonorHealth Research Institute — Scottsdale, Arizona
View Study & Checklist ➔Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
📍 Ironwood Cancer and Research Centers Scottsdale — Chandler, Arizona
View Study & Checklist ➔Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
📍 Christiana Care — Newark, Delaware
View Study & Checklist ➔A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
📍 City of Hope National Medical Center /ID# 270255 — Duarte, California
View Study & Checklist ➔A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
View Study & Checklist ➔Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.
📍 Allan Balir Cancer Center — Regina, Saskatchewan
View Study & Checklist ➔Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
📍 Rocky Mountain Cancer Centers, LLP- Aurora — Lone Tree, Colorado
View Study & Checklist ➔A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
📍 Research Site — Scottsdale, Arizona
View Study & Checklist ➔Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
📍 Yale University — New Haven, Connecticut
View Study & Checklist ➔Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
📍 University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
View Study & Checklist ➔Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis
📍 Centre Hospitalier de l'Université de Montréal (CHUM) — Montreal, Quebec
View Study & Checklist ➔Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
📍 Nebraska Cancer Specialists — Omaha, Nebraska
View Study & Checklist ➔A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
📍 UAB Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
📍 Icahn School of Medicine at Mount Sinai — New York, New York
View Study & Checklist ➔